RxDoctor Payments Data

Mary Bond, DO

Family Medicine · Fort Worth, TXNPI 1376004762

Payments from drug & device makers

$690in general payments, 2019–2025

Across 29 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tris Pharma Inc$170
  • AstraZeneca$168
  • Novo Nordisk$153
  • AbbVie$67
  • Lilly USA, LLC$36
  • GSK$29
  • plus $67 from 3 others

What the payments were for

  • Food & beverage$690100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tris Pharma Inc4$170
AstraZeneca7$168
Novo Nordisk9$153
AbbVie3$67
Lilly USA, LLC2$36
GSK1$29
Abbott1$24
Amgen1$22
Pfizer1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$690 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$71,869
Medicare patients
202
Services billed
1,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$78,809
MounjaroTirzepatide49$67,962
JardianceEmpagliflozin24$25,114
EliquisApixaban22$16,889
FarxigaDapagliflozin Propanediol17$15,920
SynthroidLevothyroxine Sodium12$1,656
Levothyroxine Sodium148$1,576
Hydroxyzine Hcl17$1,368
Atorvastatin Calcium108$1,132
Gabapentin59$873
Albuterol Sulfate HfaAlbuterol Sulfate31$830
Bupropion XlBupropion Hcl20$802
Losartan Potassium90$756
Rosuvastatin Calcium102$738
Solifenacin Succinate11$669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$153$78,80975 claims
Lilly USA, LLCMounjaro$36$67,96249 claims
PfizerEliquis$20$16,88922 claims
AstraZenecaFarxiga$168$15,92017 claims
AbbVieSynthroid$67$1,65612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →